Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

April 30, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 64 min

What were the key takeaways from Merck & Co., Inc.'s April 30, 2026 earnings call?

In the first quarter of 2026, Merck & Co., Inc. reported revenues of $16.3 billion, reflecting a 5% year-over-year increase, driven by strong performance in oncology and animal health. The company reported a loss of $1.28 per share, impacted by a one-time charge related to the acquisition of Cidara Therapeutics. Management raised the midpoint of their full-year revenue guidance to a range of $65.8 billion to $67 billion, indicating continued confidence in their pipeline and product launches, despite challenges in certain segments like vaccines.

What topics did Merck & Co., Inc. cover?

  • Revenue Growth: Merck reported total revenues of $16.3 billion for Q1 2026, a 5% increase year-over-year. This growth was attributed to strong demand in oncology and new product contributions. Management stated, "We delivered year-over-year growth with revenue of $16.3 billion, driven by continued strength in oncology, animal health and growing contributions from new products."
  • Oncology Performance: Sales of the KEYTRUDA family increased 8% to $8 billion, driven by strong demand from metastatic indications and earlier-stage cancers. Management highlighted, "Strong utilization in tumors that primarily affect women, including breast and cervical cancer, continues to be a key contributor to growth."
  • Guidance Update: Merck narrowed and raised the midpoint of its full-year revenue guidance to between $65.8 billion and $67 billion, reflecting a growth expectation of 1% to 3%. Caroline Litchfield noted, "We have narrowed the range and raised the midpoint of both our full year revenue and EPS guidance."
  • Challenges in Vaccines: GARDASIL sales decreased by 22% to $1.1 billion, driven by lower demand in China and Japan. Litchfield stated, "In Vaccines and Infectious Diseases, GARDASIL sales were $1.1 billion, a decrease of 22%, driven by lower demand in China and Japan, consistent with our expectations."
  • Pipeline Developments: Merck achieved several pipeline milestones, including the FDA approval of IDVYNSO for HIV-1 treatment and priority reviews for I-DXd in lung cancer. Davis emphasized, "We continue to see robust demand for our innovative medicines and vaccines around the world."

What were Merck & Co., Inc.'s April 30, 2026 results?

  • Revenue: $16.3 billion
  • KEYTRUDA Sales: $8 billion (+8% YoY)
  • GARDASIL Sales: $1.1 billion (-22% YoY)
  • Operating Expenses: $15.2 billion (including a $9 billion onetime charge)
  • Gross Margin: 81.9% (-0.3 percentage points)
  • Full Year Revenue Guidance: $65.8 billion to $67 billion (1% to 3% growth)

Merck's strong revenue growth and pipeline advancements position the company favorably for the future, despite challenges in certain segments like vaccines. The raised guidance reflects management's confidence in ongoing product launches and pipeline developments. Investors should monitor the execution of new product launches and the impact of the Terns acquisition as key catalysts moving forward.

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Thanks, Julie, and hello to all of you this morning. It's a pleasure to have you join us for the First Quarter 2026 Conference Call of Merck & Co, inc., based in Rahway, New Jersey, USA. On the line today, you'll hear from Rob Davis, our Chairman and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, President of Research Labs. Just before we begin, please note that our GAAP results contain things like acquisition-related charges, restructuring costs and certain other items, all of which we've taken out of our non-GAAP results. You can find a reconciliation in the press release we issued. Let me also remind everyone that a number of the things we say today could be treated as forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Statements of that kind reflect what our company's management currently believes and carry substantial risks and uncertainties. Should our underlying assumptions turn out to be wrong or should uncertainties come to pass, actual results could end up differing materially from what those forward-looking statements set forth. In our SEC filings, including Item 1A in the 2025 10-K, we identify specific risk factors and cautionary statements that might lead the company's actual results to differ materially from any projections contained in the forward-looking statements we make this morning. Merck & Co., Inc., Rahway, New Jersey USA, has no obligation to publicly update any forward-looking statements. A slide presentation will run alongside our speakers' prepared remarks during today's call. Those slides, together with the earnings release, today's prepared remarks and our SEC filings, have all been posted to the Investor Relations section of our company's website. And with that, let me hand things over to Rob.

Rob Davis

executive
#2

Thank you, Peter. Good morning, and I appreciate everyone joining us on today's call. Bringing forward and delivering breakthrough science that tackles unmet medical needs stays at the core of how we intend to create lasting value for patients and shareholders. We keep making concrete headway when it comes to speeding up and expanding our pipeline. And thanks to the new products we've recently launched, the reshaping of our portfolio into a much more varied set of commercial drivers is now clearly in motion. Moving to what we achieved in the first quarter; we posted growth compared with a year earlier, with revenue reaching $16.3 billion, powered by ongoing momentum in oncology, animal health, and rising contributions from new products. Our confidence in the outlook for 2026 is unchanged, and Caroline will address that shortly. We also hit a number of significant pipeline milestones, the FDA cleared IDVYNSO as a fresh treatment option for adults whose HIV-1 is virologically suppressed, which speaks to our continued dedication to innovation that meets the shifting needs of people living with HIV. On top of that, the FDA gave priority review to I-DXd, the antibody drug conjugate we're developing alongside Daiichi Sankyo for adult patients who have already been treated for extensive stage small cell lung cancer. Within ophthalmology, we kicked off Phase IIb/III studies in neovascular age-related macular degeneration for MK-8748, our TIE-2/VEGF bispecific antibody. That's the second candidate to come from our acquisition of iBio; we also shared key Phase III results spanning several other therapeutic areas. Lastly, in our Animal Health business, our expectations for long-term growth are high, fueled by launches of new products and those already underway. We're happy to have brought NUMELVI to the U.S. market, the first and only second-generation JAK inhibitor indicated for allergic dermatitis in dogs. Our planned acquisition of Terns Pharmaceuticals, along with its promising candidate for certain patients with chronic myeloid leukemia, stands as another illustration of our science-led business development strategy being put into practice. TERN-701 could potentially be a best-in-class therapy in a disease where there's room to further improve how deeply and how long patients respond. With the considerable unmet need for more options, we see multibillion-dollar commercial potential in TERN-701 and expect it to be a major growth driver over the next decade. This deal reflects our disciplined approach of pursuing business development whenever compelling science and value line up. And we hold firmly to the belief that TERN-701 can help patients while also creating value for our shareholders. Going forward, we still anticipate a notably strong stretch of Phase III data readouts from novel candidates across the next 18 months. Our portfolio is going through a significant transformation into one with a quickly growing and diversified set of growth drivers. We're in the middle of initial launches for more than 20 new products, nearly all of which carry blockbuster potential across a wide range of therapeutic areas. To operate with the speed and precision this opportunity calls for, we announced an evolution of our commercial operating structure. This fresh operating model for our business units, structured around therapeutic-area products, is designed to create clear ownership, tighten our strategic focus, and make us nimbler, so that each and every segment of our commercial side of the house can fulfill what our pipeline promises to patients. It's a pleasure to have Brian Ford join the executive leadership group, where he'll head up the newly created specialty, pharma and infectious diseases business unit. Meanwhile, Yani Ushausen steps in to run the newly established global oncology and MSD International business unit. Corp Guindo now leads a freshly assembled unit for strategic access policy and communications. All three of these leaders carry extensive backgrounds into these critical positions. As one team, this leadership group and the way we're structured will allow us to execute our strategy strongly — a strategy that involves deepening our oncology leadership while simultaneously constructing a robust, varied portfolio spanning multiple therapeutic areas. We have every confidence this shift puts us in the best possible spot to capture a potential commercial opportunity worth more than $70 billion by the mid-2030s, coming from these 20-plus anticipated new growth drivers by themselves. We're likewise pursuing other significant actions to speed up the transformation already underway at our company when it comes to artificial intelligence. Seven days ago, we unveiled a partnership spanning multiple years with Google Cloud aimed at expanding sophisticated AI, data and agentic capabilities throughout our organization. That builds on our recently broadened work with Tempus AI, meant to push forward our precision oncology approach, along with a fresh arrangement with the Mayo Clinic letting us tap Mayo's clinical insights and genomic data sets at scale. Taken together, these moves bolster greater efficiency throughout our company and open a genuine chance to speed innovation in our pipeline while raising how likely it is that patients ultimately receive it. Looking ahead, demand keeps coming in strong worldwide for our novel medicines and vaccines. We're putting money behind our pipeline, refining how we operate, and remain entirely dedicated to our mission of applying cutting-edge science to save and improve lives. The headway we're achieving gives us encouragement, and we anticipate numerous important milestones arriving over the coming months; to sum up, our confidence holds firm in both our strategy and our capacity to produce lasting growth and value for shareholders. Before handing things to Caroline, I'd like to acknowledge Sanat Chattopadhyay and Joe Romanelli, since both have shared their plans to retire from Merck. Sanat and Joe have left enduring marks on our company and on the patients we serve, and I thank them for all they've accomplished over the years; and with that, over to Caroline.

Caroline Litchfield

executive
#3

Thanks, Rob. Good morning, everyone. As Rob mentioned, we achieved growth this quarter, powered by ongoing momentum in Oncology and Animal Health, along with rising contributions from the numerous compelling products we've launched. Through our commercial and operational execution, we keep generating solid near-term results while moving forward our extensive, deep pipeline and putting money into innovation to create long-term value for patients, customers, and shareholders. Now let's look at our first quarter results. Revenues for the whole company came to $16.3 billion, up 5%, or 3% when you strip out foreign exchange effects. The revenue remarks that follow will be presented on an ex exchange basis. Within Oncology, sales for the KEYTRUDA family of products, which covers KEYTRUDA and KEYTRUDA QLEX, rose 8% to $8 billion, with worldwide growth fueled by sustained robust demand from metastatic indications and strong uptake in earlier-stage cancers. Heavy use in tumors that mainly impact women, such as breast and cervical cancer, remains a major driver of growth. Beyond that, we observed greater use of KEYTRUDA combined with Padcev in locally advanced or metastatic urothelial cancer; within the U.S., growth gained roughly $250 million thanks to purchase timing. We're happy with the positive response after the recent launch of KEYTRUDA QLEX, which posted $128 million in sales for the quarter. On April the 1st, the permanent J code came through, and we're eager to make an even bigger difference for patients and health care systems. Our wider oncology portfolio delivered yet another quarter of robust growth. In particular, WELIREG sales climbed 43% to $199 million, propelled by sustained uptake from continuing launches in international markets and greater use in certain patients in the U.S. with previously treated advanced renal cell carcinoma. We're looking forward to potentially helping more patients with renal cell carcinoma, after encouraging results from the LITESPARK-011 and -022 studies. Over in Vaccines and Infectious Diseases, GARDASIL sales reached $1.1 billion, down 22%, because of weaker demand in China and Japan, which matches what we anticipated. In the U.S., sales fell 10%, mainly from CDC purchase timing, partly offset by price. On pneumococcal, CAPVAXIVE keeps making solid progress, with $142 million in sales, up 31%. Beyond the U.S., sales came from uptake tied to continuing launches in certain markets. Within the U.S., growth came from higher demand among both retail pharmacies and nonretail customers, partly offset by a decrease in wholesaler inventory; in Cardiometabolic and Respiratory, WINREVAIR keeps having a positive effect on patients with pulmonary arterial hypertension. Global sales hit $525 million, reflecting the sustained strong demand for this important therapy. In the U.S., we kept seeing steady progress, with more than 1,600 new patients having gotten a prescription and greater usage among patients whose background therapies do not include a prostacyclin. Outside the U.S., we keep moving forward on securing reimbursement and ongoing launches. OHTUVAYRE, which is a new maintenance therapy for adults living with COPD, generated $131 million in sales. Those sales took a hit, as we had anticipated, from the CMS reimbursement change and from Medicare deductible resets; even so, prescription trends give us encouragement, since they started bouncing back in March. In line with our approach of realizing the full strong potential of OHTUVAYRE, we are putting money into reaching additional patients and physicians, and we anticipate that this will speed up growth during the back half of the year and afterward. Our Animal Health segment posted yet another quarter of robust growth, with a 6% rise in sales. Livestock sales were up 8%, mainly because of stronger demand for ruminants and poultry products, along with price. Companion animal sales rose 4%, owing to new product launches and price, though a decline in vet visits partly offset that. I'll now take you through the rest of our P&L, and everything I say will be on a non-GAAP basis. Gross margin came in at 81.9%, down 0.3 percentage points. Operating expenses rose to $15.2 billion, a figure that includes a $9 billion onetime charge tied to acquiring Cidara Therapeutics. If you set that charge aside, operating expenses were up 2%, which reflects larger investments backing our key growth drivers, partly offset by gains from our multiyear optimization effort and by recognizing a portion of the external funding for sac-TMT. Other expense climbed to $318 million, chiefly a reflection of financing connected to recent business development transactions. Our tax provision was $957 million. Because of the nontax deductible onetime charge for Cidara, we posted a pretax loss this quarter, which produced a tax rate of negative 43.5%. All told, we reported a loss of $1.28 per share, and that figure includes a negative impact of $3.62 per share from the onetime charge related to Cidara. Now let's turn to our 2026 non-GAAP guidance. We have narrowed the range and lifted the midpoint for both our full year revenue and EPS guidance. Revenue is now projected to land between $65.8 billion and $67 billion, which works out to growth of 1% to 3%, and that includes a positive foreign exchange impact of roughly 1 percentage point using mid-April rates. Our gross margin assumption is still approximately 82%. Operating expenses are assumed to fall between $36 billion and $36.8 billion; this range leaves out the proposed acquisition of Terns as well as any other significant potential business development transactions. Other expense should come to approximately $1.3 billion. We assume a full year tax rate between 23.5% and 24.5%, which reflects the nontax deductible onetime charge for Cidara; we assume approximately 2.48 billion shares outstanding. All told, we expect EPS of $5.04 to $5.16, including a positive foreign exchange impact of approximately $0.10 using mid-April rates. It's worth noting that this guidance leaves out the impact of the proposed acquisition of Terns, which should close soon. We expect that transaction to produce a onetime charge that will raise research and development expense by approximately $5.8 billion, or approximately $2.35 per share. Beyond that, continued spending to push TERN-701 forward, plus the financing costs we're assuming, will reduce EPS by roughly $0.12 in the current year. As you work through your models, a few things are worth keeping in mind. With KEYTRUDA, remember that although growth got a lift from the timing of wholesaler purchases during the first quarter, we'll see a matching headwind when the third quarter arrives. On ENFLONSIA, just as in the first quarter, we anticipate minimal sales in the second quarter, reflecting both the seasonal pattern of the product and the persistently high levels of RSV monoclonal antibody inventory sitting in the market. We're actively working with customers ahead of the RSV season, and we stay focused on teaching health care professionals and parents why it matters to protect infants from this potentially serious disease, and we expect shipments to pick up during the second half of the year. Finally, we anticipate SG&A expenses will rise across the rest of the year as we put money into maximizing the impact of our recent and upcoming launches; shifting now to capital allocation, our strategy hasn't changed; we'll put investments in our business first to fuel near- and long-term growth, including new product launches and a robust pipeline. We stay dedicated to the dividend, aiming to raise it over time. Business development continues to rank as a high priority, as our recently announced acquisition of Terns shows. Within a strong investment-grade credit rating, we retain the capacity to pursue further science-driven, value-enhancing transactions down the road; we're on track for share repurchases of approximately $3 billion this year, consistent with what we said previously. To wrap up, we're confident about our business outlook, powered by global demand for our innovative medicines and vaccines, including the many new products we're launching. We stay dedicated to delivering medically significant innovations that will let us bring value to patients, customers and shareholders far into the future. With that, I'd like to hand the call over to Dean now.

Dean Li

executive
#4

Thank you, Caroline. Good morning. We kept moving forward at a consistent pace on both the clinical and regulatory fronts. In my remarks today, I'll cover cardiometabolic and respiratory, then oncology, infectious diseases, and ophthalmology, and I'll wrap up with the important milestones ahead. Let me begin with cardiometabolic and respiratory. Atherosclerotic cardiovascular disease continues to weigh heavily on patients around the world. And given that clinical guidelines were recently updated to recommend lower LDL-cholesterol thresholds, innovation that is broadly accessible is still needed. At last month's American College of Cardiology Congress, further Phase III data were shared for enlicitide, our oral PCSK9 inhibitor still under investigation. Enlicitide is intended to lower LDL cholesterol much like PCSK9 antibody therapies do, but with the convenience of one pill taken daily. In the Phase III CORALreefAddOn study, when added on top of background statin therapy, it produced statistically significant and clinically meaningful LDL-cholesterol reductions at 8 weeks that were greater than those seen with other oral add-on lipid-lowering therapies. Notably, enlicitide likewise demonstrated statistically significant greater reductions on key secondary endpoints, among them apolipoprotein B and non-high-density lipoprotein cholesterol. The CORALreef program has produced compelling evidence supporting enlicitide's efficacy and safety. As a pill, enlicitide could democratize access to a potent therapy for lowering lipids. With clinical guidelines now aiming at lower LDL-cholesterol targets, preventive cardiology is increasingly energized and centered on early, aggressive LDL-cholesterol reduction. Also at ACC, we presented the complete results of the Phase II CADENCE trial, which assessed WINREVAIR in adults who have combined post- and pre-capillary pulmonary hypertension along with heart failure with preserved ejection fraction. WINREVAIR hit the primary endpoint of reduction from baseline in pulmonary vascular resistance versus placebo. At the 0.3 milligram per kilogram dose, WINREVAIR extended the time to first occurrence of a clinical worsening event, an exploratory secondary endpoint, with a hazard ratio of 0.18. These results offer compelling proof-of-concept and justify further evaluation in Phase III. This condition is underdiagnosed and carries an extremely poor prognosis. No therapies are currently approved. Turning to Oncology, KEYTRUDA now holds 44 FDA-approved indications spanning 19 tumor types, plus 2 tumor-agnostic approvals, and keeps generating evidence that further transforms cancer care. During the first quarter, the FDA and European Commission approved KEYTRUDA in combination with paclitaxel, with or without bevacizumab, for treating certain patients who have platinum-resistant ovarian cancer, drawing on the findings of KEYNOTE-B96. This is the first PD-1 inhibitor based regimen to show a statistically significant improvement in both progression-free survival and overall survival versus paclitaxel with or without bevacizumab for these patients. We also announced findings from the KEYNOTE-B15 study showing that KEYTRUDA plus Padcev cut the risk of event-free survival related events by 47% and the risk of death by 35% among cisplatin eligible patients with muscle invasive bladder cancer. This is the first and only perioperative immunotherapy plus ADC regimen to extend survival for these patients. On the strength of these data, the FDA has accepted supplemental BLA filings for KEYTRUDA and KEYTRUDA QLEX under priority review and is targeting an action date of August 17. KEYNOTE-B15 marks the sixth time a regimen containing KEYTRUDA has shown an overall survival benefit in an earlier stage of cancer, and should it gain approval, it would become the 12th earlier-stage indication for KEYTRUDA. Progress also continues across our wider oncology portfolio. WELIREG, our first-in-class oral HIF-2-alpha inhibitor that was initially approved to treat certain patients with von Hippel-Lindau syndrome, has now generated further clinical data in renal cell carcinoma spanning multiple stages of the disease. The LITESPARK-022 study, which assessed WELIREG together with KEYTRUDA in the adjuvant setting, showed a 28% lower risk of disease recurrence or death relative to KEYTRUDA by itself. Separately, the LITESPARK-011 study, which evaluated WELIREG combined with Lenvima, showed a 30% lower risk of disease progression or death in certain patients with advanced RCC when compared with cabozantinib. Supplemental applications for WELIREG in combination with KEYTRUDA or KEYTRUDA QLEX, based on LITESPARK-022, received priority review from the FDA, with a PDUFA date of June 19. For WELIREG plus Lenvima, based on the LITESPARK-011 study, the FDA set a PDUFA date of October 4. As we announced last week alongside our partner Eisai, the combination regimens from LITESPARK-012 failed to meet the dual primary end point of progression-free survival and overall survival in the first-line treatment of patients with RCC when compared with KEYTRUDA plus Lenvima. What we learned from that study informs the broader program. Studies within the LITESPARK clinical program, among them LITESPARK-033 and 034, which are evaluating WELIREG combined with zanzalintinib, continue to enroll. Together with our partner Daiichi Sankyo, we announced that the biologic license application for ifinatamab deruxtecan, or I-DXd, for treating extensive-stage small cell lung cancer in certain patients whose disease has progressed, has been granted priority review by the FDA; the filing rested on results from the Phase 2 IDeate-Lung01 trial and the Phase 1/2 IDeate-PanTumor01 trial. The FDA has assigned a PDUFA date of October 10. As Rob noted, we keep looking for external opportunities that can strengthen and diversify our pipeline, most recently through the proposed acquisition of Terns Pharmaceutical. TERN-701, a novel oral allosteric inhibitor targeting the BCR::ABL oncogene, is under evaluation for treating certain patients with chronic myeloid leukemia, and it could become an important addition to our expanding hematology pipeline. Clinical data has demonstrated encouraging activity, with promising rates of major molecular response and deep molecular response by week 24. Notably, this includes responses among patients with high disease burden who had already received multiple lines of therapy. We look forward to working with the talented team at Terns to move this program forward promptly. Now to HIV. Last week, the FDA approved IDVYNSO, our once-daily, single-tablet 2-drug regimen of doravirine and islatravir, a next-generation nucleoside reverse transcriptase inhibitor that blocks translocation, indicated for treating certain adults whose HIV-1 is virologically suppressed, based on 2 Phase III SWITCH study. Approval had already been granted in Japan. IDVYNSO stands as the initial two-drug regimen to gain approval that leaves out an integrase strand transfer inhibitor. During CROI, further findings were shared showing it was noninferior, with a comparable safety profile at week 48, when set against the three-drug, INSTI-based option, Biktarvy, among adults who had never before gotten antiretroviral treatment. Also, IDVYNSO demonstrated it could sustain virologic suppression at week 96 in adults who had transitioned from certain other oral antiretroviral therapies, Biktarvy included. Islatravir, a strong long-acting antiviral serving as an anchor for further regimens, is right now under assessment in late-phase trials as a once-weekly pairing with Gilead s lenacapavir, an HIV capsid inhibitor, and apart from that, alongside ulonivirine, a non-nucleoside reverse transcriptase inhibitor developed internally. Our intention is to share data from our HIV pipeline at a medical meeting coming up. Turning to RSV. In February, favorable new results were reported for ENFLONSIA regarding prevention of RSV lower respiratory tract disease among infants and children below 2 years of age who face heightened risk of severe disease across 2 seasons, drawn from the Phase III SMART study; these results are going to be provided to global regulatory authorities, aiming to secure a broader indication.

Dean Li

executive
#5

Globally, RSV ranks among the top reasons infants end up in the hospital, and it poses particular danger to kids below 2 years old who face elevated risk of severe illness. These findings add further support for ENFLONSIA when it comes to preventing RSV among younger children still at risk as they head into a second season. Earlier this month, the European Commission granted approval to ENFLONSIA for preventing RSV lower respiratory tract disease in newborns and infants in their first season, drawing on the Phase IIb/III CLEVER and Phase III SMART trial. Moving on now to ophthalmology. We remain focused on retinal conditions driven by vascular leakage and neovascularization, aiming to improve how patients fare structurally and functionally while easing the toll of certain retinal diseases. This month, we launched 2 pivotal Phase IIb/III trials studying MK-8748, an investigational bispecific Tie-2 agonist/VEGF inhibitor that we are developing for neovascular age-related macular degeneration. Those studies, MALBEC and TORRONTES, are the first to be conducted under a broader late-phase development program for MK-8748. Our move to advance development was based on positive findings from the Phase I/IIa RIOJA trial. Before we close, there's a lot coming up across our therapeutic areas in the months ahead. On the oncology side, I'd ask you to save the date for our yearly investor event, which takes place the evening of Monday, June 1, during the ASCO Annual Meeting in Chicago — we'll share where our oncology pipeline and strategy stand. On the regulatory side, as we mentioned, we could see approvals for KEYTRUDA combined with Padcev in MIBC, for WELIREG in broader RCC settings, and for I-DXd in extensive stage small cell lung cancer. Turning to HIV, we have data coming from the Phase III ISLEND-1 and 2 trials, which are evaluating islatravir and lenacapavir as a once-weekly oral 2-drug regimen that we're developing with Gilead. Regarding cardiometabolic and respiratory, things are moving forward on two fronts: the September 21 PDUFA date for the WINREVAIR label update, which draws on the Phase III HYPERION study, and the Commissioner's National priority Voucher Process for enlicitide. On the immunology side, we have data for tulisokibart, our TL1A inhibitor, coming out of the Phase III ATLAS-UC trial in ulcerative colitis along with the Phase II ATHENA study in SSc-ILD. Then in ophthalmology, there's information from the Phase III BRUNELLO study of MK-3000, our novel Wnt agonist, which is being evaluated in patients with diabetic macular edema, plus the Phase II portion of the RIOJA study of MK-8748, being evaluated for treating patients with certain retinal diseases. I'm looking forward to sharing more updates as the year goes on. Peter, I'll hand things over to you now.

Peter Dannenbaum

executive
#6

Appreciate that, Dean. Julie, let's move into the Q&A at this point. We'd be grateful if the analysts could keep it to one question apiece today, which would let us wrap up the call right at the top of the hour. Thanks.

Carter Gould

analyst
#7

Perhaps we could begin with the pipeline and MK-3000. What's your ultimate thinking on dosing? The 1-year BRUNELLO data probably won't tell us much about duration interval, and the Lucentis comparison will leave many questions unresolved. I completely understand that 40% respond suboptimally to VEGF, but can this reach your targets if it ends up needing dosing every 4 weeks? Or to put it another way, do you have reasons for conviction about every week or every 12-week dosing?

Dean Li

executive
#8

Thanks so much. Stepping back, MK-3000 is our potential first-in-class novel candidate targeting the Wnt pathway — for retinal vascular disease. Nearly all other mechanisms rely on VEGF. And as you pointed out, up to 40% have a suboptimal response to VEGF; regarding dosing, frequency, when one kind of runs these trials, once you start at every 24 weeks and after doing that, then you move further from that. So we believe one should focus on Q4 weeks, but one should not only focus on Q4 weeks; so your question, which I think hints at, is whether we're considering other frequencies — the answer is absolutely yes. But the initial focus is on 4 weeks because that is very important to get into the label. I also want to highlight really quickly that it's not just MK-3000, it's MK-8748, which is the novel bispecific directly agonizing Tie-2 that we're also excited about, and that as well is advancing in Phase IIb/III trials in retinal vascular disease.

Jason Gerberry

analyst
#9

I've got an update and a question regarding the recent WELIREG clinical update on LITESPARK-012. What I'd like to know is whether you see any worrying read-through here to some of the ongoing readouts for LITESPARK-022, and to the ability to observe an OS benefit in that setting. On top of that, you have another frontline study with WELIREG, though it sits in a post-PD-1 setting. So I'm just kind of curious whether you could address some of the read-throughs to some of the trials that are still ongoing.

Rob Davis

executive
#10

Jason, we were having a hard time hearing you. Let me restate the question, and then I think I'll get it. What I think you're asking is this: given the LITESPARK-12 outcome, how does that shape our thinking about getting OS in some of the upcoming LITESPARK studies, and what's our overall view as it relates to WELIREG. I think that's the way I was trying to ask.

Dean Li

executive
#11

I appreciate that — the audio wasn't coming through clearly for me. As for the others, such as LITESPARK-022 and LITESPARK-011, with PDUFA dates falling in June and October, our outlook on their outcomes is quite optimistic. Then, regarding your question about what the readout shows for that study involving 3 agents — a PD-1, a VEGF TKI, and a HIF-2-alpha — we're currently examining those data, though I'd be hesitant to claim it carries any unfavorable meaning for other trials, say one combining a VEGF TKI with WELIREG, or a PD-1 with WELIREG.

Michael Yee

analyst
#12

As we get closer to ASCO, you'll clearly have your SAC PMT highlighted in lung cancer, and of course PD-1 VEGF will also be featured in a plenary from a competitor, so how are you weighing the interplay of a sac-TMT alongside PD-1 VEGFs and your own Lenova asset, and maybe speeding that up? And could you just give us a quick picture of where these 2 kinds of programs currently stand?

Dean Li

executive
#13

Yes; so I'll take the question one by one as well, but I'll also address what I believe you're hinting at, which is whether those could be combined. So when it comes to the PD-1 VEGF, this is an area we're quite interested in. We presented some promising early data at AACR; and our construct for the leading PD-1 VEGF is the closest match to ours. And so we're reviewing our own data. But honestly, we're also reviewing the wider field too. And so we're keen to advance PD-1 VEGF Ford in our trials. And one of the things we think, in our hands, is that if a PD-1 VEGF were to outperform KEYTRUDA, we have a plethora of agents that could gain from being combined with either KEYTRUDA or a KEYTRUDA plus or a PD-1 VEGF. So we're pushing that forward. When it comes to sac-TMT, my belief is that at ASCO, our strong partner and collaborator Kelen will present optotroplung-05 in first-line non-small cell lung cancer. And I think people will examine that data very carefully because it may have implications for our global trials, which are not only within China but throughout the globe; regarding the question you raised, is there any possibility of considering combining those — the answer is absolutely yes. And we're gathering the information and also taking a scan to the outside world as to where and when it's best to combine a PD-1 VEGF with the rest of our portfolio.

Asad Haider

analyst
#14

Congratulations on everything you've accomplished. Perhaps a big-picture question going back to BD — you've been quite active in a number of areas, and you're saying you're ready to go after more transactions; so just orient us on where you still see the largest holes in your portfolio that more BD could fill as you survey the therapeutic landscape? What's the right deal size now? And is there a level at which the BD lever begins to matter less, given your rising confidence in the growth trajectory from the middle of the next decade thanks to the portfolio transformation already in motion?

Rob Davis

executive
#15

Yes. Asad, I appreciate the question. I'd begin by saying we have a great deal of confidence in the assets we hold, the new assets we brought in via business development, and the continued progress we're making with our pipeline. So that carries on and expands; that said, we also keep our attention on business development. And as we've stated before, we don't really aim at particular therapeutic areas as the first thing we ask; we always pose the first question, which is where do we find a meaningful unmet scientific opportunity where the science is compelling and can address; and doing that lets us consider where to concentrate. So we begin with the science; we then ask how it fits strategically, and then we turn to the value question, and where we see science and value aligned, we act. So that hasn't changed. Our approach continues to be that as our focus. On size, we keep looking anywhere from $1 billion to $15 billion, with that being roughly the sweet spot; but as we've said consistently, we have the capacity to go past that for the right strategic deal; and we will, if and when we see it; so that's where we're looking as far as therapeutic areas where we still see interesting science — obviously, oncology remains an area with a lot going on. We keep looking. Immunology is an area where we still see interesting opportunities, and cardiometabolic is probably the 3 most likely areas, but we're willing to be opportunistic beyond those too. And I guess Peter did remind me of one part. When will we feel less urgency to do a deal. My view is we can always do better. We can always grow stronger; and if we have the capacity, we'll keep investing. As Dean has said, we think in terms of one pipeline, whether internal or external. And so that combination of internal plus external will remain an ongoing part of our strategy — you won't see that change.

Vamil Divan

analyst
#16

Let me return to Win Revere for a moment. I value what you shared regarding the cadence data in ACC. I'm wondering whether you might offer any fresh perspective on where things stand with the FDA as you work toward advancing the Phase II program in that setting, and whether you still feel confident that clinical listening can serve as the primary endpoint for Phase III. Beyond that, perhaps a ballpark sense of how much time you believe would really be needed to carry out a Phase III study in this indication.

Dean Li

executive
#17

Yes. Many thanks; regarding Wind River, what I'd say is that it is redefining the standard of care in PAH. So now the real question becomes whether we are able to shift it into another segment of pulmonary hypertension — namely, individuals who have heart disease. The group of patients we've selected represents a comparatively modest subset among those who have pulmonary hypertension alongside heart disease; yet it may well rank among the largest unmet needs I'm aware of within this group, which — at least as I would frame it — differs greatly from the PAH population. One might even call it more complex, since these patients are older and carry more comorbidity. In our view, the cadence provides that proof of concept — as I mentioned before, discussing reductions in PVR as the primary endpoint is all well and good. However, for my part, with this group of patients, having endpoints that let someone — and by someone I mean patients, providers and payers — truly perceive a compelling conglomerate of endpoints in the time to clinical worsening will matter enormously. And that is precisely where our discussions with the FDA will take place. Another point I believe will matter is pinning down the inclusion criteria together with the FDA and also the wider community, in terms of how you genuinely operationalize the clinical trial, while also making it crystal clear to everyone that in our thinking, this is an orphan patient population.

Daina Graybosch

analyst
#18

Yes. I'd like to return to ASCO and the results we'll be seeing from Kalon regarding OptiTROP-Breast05. That trial is in China. And I'm curious what we ought to bear in mind when we examine those findings, in terms of how they might or might not carry over on a global scale — any distinctions in what you're running globally? Or anything else to bear in mind.

Dean Li

executive
#19

Yes. Many thanks for asking that. So, rising to a broader view, our view is that sac-TMT is a go-to ADC, yet we feel it carries some meaningful differentiation. And we believe sac-TMT could be — I think Elliot has frequently described it as a cornerstone, and Margaria called it a workhorse ADC. And we have 17 Phase III studies, 13 of which are in first movers; we have one in blast, non-small cell lung cancer, gyn, gastric and bladder. When we run our trials and when we talk with our close partner, Kalon, we rely on the fact that they are, in a sense, conducting signal finding within registrational trials in China; and we acknowledge China differs, yet these data matter to us; regarding the precise specifics of sac-TMT and the Kian, I'd simply remind you that with OptiTROP-Breast05, data will be available. But I think it's crucial to pause and consider, if — how a person reasons through that in terms of how that might read out; we are tracking their data closely. But I think we are guided we are guided by the results. I do want to stress that in their OptiTROP, it's sac-TMT plus KEYTRUDA versus KEYTRUDA in PD-L1 positive first-line non-small cell lung cancer. And it matters greatly that if someone wants to run an ADC plus KEYTRUDA versus KEYTRUDA within the United States, ex China, one must examine where a PD-1 stands and what's the range for the PD-L1 cut-off. And so for us, this is the initial Phase III combination study of sac-TMT and KEYTRUDA to read out. We have 50% of our Trou studies evaluating KEYTRUDA combos in our TrophUse-007, our global study of ACTMT and KEYTRUDA versus KEYTRUDA in TPS greater than 50% in first-line non-small cell lung cancer. And I stress that simply because within the United States and ex China, TPS greater than 50% is where KEYTRUDA holds an indication.

Steve Scala

analyst
#20

Which factors are controlling whether the FDA will accept the enlicotide filing? Also, Dean, could you address the adjustments being made regarding titration? Which shorter timeframes are you aiming for? Also, does the 15 minutes mentioned earlier come before or after the drug is given?

Dean Li

executive
#21

Right; I'd simply state that with enlicitide, as we've mentioned, our aim is to provide the first and finest potent oral PCSK9. Its design closely mirrors that of an antibody. The Phase III results, as we've talked about, I believe set forth the value proposition and its connection to potency across all the key by proteins; regarding the CNPV, the matter tied to the CNP is simply so all of us grasp that the NPD pathway operates somewhat differently, meaning we — you could almost view it as a rolling submission. Through that rolling approach, once that rolling submission concludes, that's the point when the FDA steps in and issues you a letter along with a PDUFA date; thus we are currently engaged in those talks with the FDA; and then, as is our custom upon receiving formal acceptance of the entire file, which differs somewhat under the CMPB, we will put out an announcement. I want to stress that during our dialogue with the FDA, what matters greatly to them is us genuinely demonstrating that the CMPD program is significant, that we're tackling a major U.S. public health emergency, that we're providing innovative treatments, and that we're boosting domestic drug manufacturing and supply chain resilience. So all of those matter to the FDA, and our conversations with them are truly productive. Thus I believe things are going quite well, and it's moving along nicely. I'd expect that our projection of possibly securing approval in the second half of this year — I see no grounds to question that right now. Regarding what you brought up about the matter of how one would take it — we're likewise in talks with the FDA about the precise label concerning how they'll describe prescriptions and the timing and method of taking it. I don't wish to get ahead of that discussion since those talks are highly active at this very moment.

Chris Schott

analyst
#22

I wanted to check in regarding TL1A. My sense is that this particular program has drawn somewhat less focus compared with a few of your other late-stage data disclosures slated for this year. Could you share your perspective on what part TL1A might play within the IBD arena? And perhaps on a wider level, whenever we consider immunology alongside IBD, conversations seem to be growing around combo treatment as possibly the market's next phase. What catches my interest is how Merck is positioning itself here, extending from TL1A toward a wider pipeline?

Dean Li

executive
#23

Sure. To start, I'd say that across the immunology discipline, specific nodes carry major significance — 23 is a significant node. TNF is a significant node. That's the way the discipline has been arranged; we ask ourselves if TL1A qualifies as one such node, and it's our expectation that laSocobar might emerge as 1 of the earliest and finest-in-class TO1As; so it fits within that kind of structure. Another point you just raised, which I believe matters greatly, is the growing curiosity about pairing these distinct nodes together. People attempted this 10, 15, 20 years back, and the results were not good. Yet currently the evidence indicates that under particular circumstances, combining becomes feasible. If you examine the AE profile for tubasocopart — looking at the Phase II data, and not merely our own Phase II data, but throughout the Phase II data — while it belongs to the TNF superfamily, in terms of AE profile I'd characterize it as a gentler, softer AE profile relative to other NOTO-TNFs, alongside powerful efficacy. So I believe combinations are going to be adopted. Regarding what we anticipate for Phase III ulcerative colitis as well as chronic and Crohn's disease, results are on the way and we expect to be the first mover, though I'd also stress that we additionally believe TL1A could stand apart not only as a significant node, but potentially as relevant for more than just inflammation or its dampening — it may also matter for fibrosis. What's more, we have Phase II data for SSC ILD and for HS arriving during 2026. That, we hope, will establish the distinctive role or distinctive standing that T1 holds alongside all the other key nodes.

Louise Chen

analyst
#24

I'd like to raise a question regarding the CADENCE study. Your recent data, presented at a medical meeting, generated a certain amount of discussion. What do you believe the Street might be failing to appreciate when it comes to how competitive your product is?

Dean Li

executive
#25

Honestly, I can't be certain I'm tracking every point you have in mind. Regarding how competitive our product is, the only way I can really respond is this: from a rival-treatment perspective, I'm not aware of anything approved for this group of patients. Looking ahead, I'm not convinced I can identify anything that would get past that hurdle. As for whether a Phase III study can be run in a way that mirrors what the Phase II showed, that's really the central question, and it's the same question we've been discussing with KOLs as well as with the FDA. Everyone clearly recognizes that this group of patients has an enormous unmet need. So I wouldn't really describe the situation as a competitive one in that sense. The real question is whether, for the first time, a truly compelling option can be offered to patients who urgently require one.

Umer Raffat

analyst
#26

I was hoping to dig into a bit of extra detail that emerged regarding your turns deal — something I believe we didn't cover on the earlier call you did. If I run the numbers, it seems the additional patients might have shown an MMR achievement rate around 2 out of 10, or in that vicinity. Could you address that decline and say whether it alters, or leaves unchanged, how you view the drug's profile overall? Since presumably that represents the real target population during the early phase of launch?

Dean Li

executive
#27

Yes. I really appreciate that question. What I'd say is that within this — within CML, several therapies have received approval, and there does appear to be a substantial unmet need. The value proposition for us with turns to 101 comes down to whether it can potentially be a best-in-class Alister TKI, featuring high selectivity along with an improved therapeutic index. When data gets presented at certain meetings early on, frequently it's framed in a single manner. For us, though, it's genuinely important to consistently examine that data — particularly when you attend ASCO, AACR or ASH — we review it right away through the lens of how you'd think about registration. It matters greatly to convert whatever an abstract states into what I'd call a more conservative ITT population aligned with regulatory standards. With that in mind, what was shared at those public congresses is turn stated to 75% MMR and 36% DMR achievement rate. As the data matured and we examined highly specific patient-level data, we believe the MMR will be north of 50%; and within the confidence interval as had been publicly stated. We think an MMR in roughly that range is extremely compelling. Then the other thing I'd point out is that we also consider the DMR rate quite interesting to examine, and whether this drug might not only establish a best-in-class position with respect to MMR, but might also push the field toward increasingly viewing DMR as a treatment goal.

James Shin

analyst
#28

James, thanks for the question. Could you help us tell MK-6837 apart from sac-TMT? Then, returning to what was asked about TL1A: inside Merck, do we believe TL1A can succeed on its own in immunology, given that from a market or commercial standpoint, immunology appears to be a strategy heavily driven by portfolios? Several of your competitors hold sizable portfolios, and there's a highly competitive remote that has been established around that, right?

Dean Li

executive
#29

All right, so allow me to address the immunology matter very plainly. TL1A is where our attention is firmly placed, yet if you were to ask whether our goal is to halt at TL1A — would we treat TL1A as a beachhead for broadening and extending — the response is that we would certainly take it forward to broaden and extend. We had broadened from IBD into additional conditions, and we would move it ahead into conditions where combining immunofibrosis would matter greatly. Regarding other molecules, naturally, if someone possessed a leading TL1A capable of progressing across the sequence of various indications we hold, then within each one of those indications you would right away consider what the combinatorial partner should be, whether that's in IBD, HS, or SSC IOD. So we would right away consider pursuing that too. Thus TL1A holds our attention, but that attention doesn't put us in a position where we aren't considering not only whether we can be first and best, but also what comes next. And I believe the remaining question concerned MK-6837 — is that right? I didn't catch the other one. MK-6837 is a separate ADC featuring a distinctive payload, and we have halted it, particularly given the profound effect of sac-TMT, and also in relation to — we've consistently stated that within the ADC space we're greatly interested in altering the target as well as altering the payload, and in considering combining or cycling distinct payloads as the antibody drug conjugate field continues to develop.

Rob Davis

executive
#30

Perhaps I can throw in 1 small extra item as a preview, something related to what you'll observe as we head into next year and past that. Within our invisible pipeline, we frequently mention that additional assets exist in the immunology space which you aren't currently seeing. So, simply to back up what Dean said, we are not merely a TL1A company. Beyond that, we have other programs in development. And as time goes on, you'll begin to gain a clearer picture of that once we unveil it as it enters Phase I. All right. Thank you, James. We'll fit one final question in prior to wrapping up the call.

Geoff Meacham

analyst
#31

Alright. Dean, when it comes to HIV, with Avito having just been approved recently, could you discuss how you view the competitive landscape, and on a related note — I realize you've got a presentation coming — how significant a strategic priority is HIV and infectious disease when you consider the broader BD strategy?

Dean Li

executive
#32

Regarding where our interest lies with HIV, we have a deep level of interest in our HIV program specifically. Anyone who has spoken with Eliot Bar, our Chief Medical Officer, I believe can sense that simply from his demeanor. Islatravir belongs to the next generation of nucleoside reverse transcriptase inhibitors; its mechanism involves blocking translocation, and we have the daily regimen — and interest keeps growing in moving from a daily regimen of 3 drugs down to 2. Among those daily 2-drug regimens, I believe we are the sole ones lacking an entity backbone. That, I think, matters greatly. Also crucial is our belief that ezlotivir is capable of anchoring to weekly dosing, and you observe this in later lenacapavir, a 2-drug combo that hopefully becomes the first Q week option, followed by loci with UL, currently in development, with data to be presented, I think, in due course — it might be the smallest pill, could offer a favorable DDI profile, and be extremely effective. Then, as you mentioned, for me, the monthly option — if you could have 12 pills and protect people with MK 852 — I think that would be an incredibly important contribution as a commercial product, but equally as a global product for public health around the world. So if the question is whether we are committed, and whether we are passionate about our HIV program, I hope the tenor of my response made clear that the answer is unequivocally yes.

Peter Dannenbaum

executive
#33

That's great. Geoff, thank you, and thank you to everyone. Sorry we ran a few minutes long. If anything else comes up that you'd like to ask about, just reach out by phone. Thanks.

Operator

operator
#34

Thank you for your participation. Participants, you may disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.